Bone Biologics grants director 113,896 stock options

The award vests in four equal quarterly installments, except as otherwise provided in the award notice.

(Neutral)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Bone Biologics Corp director Robert E. Gagnon was granted non-employee stock options covering 113,896 Common Stock shares on September 28, 2026, at an exercise price of $0.50 per share. The report also lists directly held options for 10,483 shares at $5.28, 5,119 at $10.38, 2 at $25.44, and 1,335 at $25.44; these existing options are fully exercisable.

Insider Trade Summary

Grant/Award: 113,896 shares

Grant/Award 5 txns

Insider Gagnon Robert E.

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Non-Employee Stock Option ^F1	113,896	$0.00	$0.00
holding	Non-Employee Stock Option ^F2	--	--	--
holding	Non-Employee Stock Option ^F2	--	--	--
holding	Non-Employee Stock Option ^F2	--	--	--
holding	Non-Employee Stock Option ^F2	--	--	--

Holdings After Transaction: Non-Employee Stock Option — 130,835 contracts for 16,939 underlying shares (Direct)

Footnotes (2)

F1. This option was granted under the Bone Biologics Corporation 2015 Equity Incentive Plan, in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, vests infour equal quarterly installments.
F2. This option is fully exercisable as of the date of this report.

Key Figures

New option award: 113,896 options covering 113,896 Common Stock shares Award exercise price: $0.50 per share Existing option position: 10,483 underlying Common Stock shares; $5.28 exercise price +3 more

6 metrics

New option award 113,896 options covering 113,896 Common Stock shares Granted September 28, 2026

Award exercise price $0.50 per share New non-employee stock options

Existing option position 10,483 underlying Common Stock shares; $5.28 exercise price Expires June 4, 2035; fully exercisable

Existing option position 5,119 underlying Common Stock shares; $10.38 exercise price Expires September 17, 2034; fully exercisable

Existing option position 2 underlying Common Stock shares; $25.44 exercise price Expires January 8, 2034; fully exercisable

Existing option position 1,335 underlying Common Stock shares; $25.44 exercise price Expires January 8, 2034; fully exercisable

Key Terms

Non-Employee Stock Option, 2015 Equity Incentive Plan, Rule 16b-3, fully exercisable

4 terms

Non-Employee Stock Option financial

"Non-Employee Stock Option"

2015 Equity Incentive Plan financial

"granted under the Bone Biologics Corporation 2015 Equity Incentive Plan"

Rule 16b-3 regulatory

"in a transaction exempt under Rule 16b-3"

Rule 16b-3 is a Securities and Exchange Commission regulation that exempts certain routine, pre-approved transactions by company insiders from automatic liability for short-term trading profits. It acts like a safe harbor: if an insider follows a formal plan or the board approves specific transactions in advance, profits from buying and selling company stock within six months are not automatically reclaimed. Investors care because the rule clarifies when insider trades are permissible and reduces uncertainty about potential clawbacks.

fully exercisable financial

"This option is fully exercisable as of the date of this report"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stock-option award did BBLG director Robert E. Gagnon receive?

Robert E. Gagnon, a Bone Biologics Corp director, received options covering 113,896 Common Stock shares on September 28, 2026, at an exercise price of $0.50 per share. The options vest in four equal quarterly installments, except as otherwise provided in the award notice.

When do Robert E. Gagnon's existing BBLG stock options expire?

The report lists directly held options covering 10,483 shares expiring June 4, 2035; 5,119 shares expiring September 17, 2034; and two positions covering 2 and 1,335 shares, each expiring January 8, 2034.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 09/30/2026 - 05:15 PM Accepted by SEC EDGAR 09/30/2026 - 05:14 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Gagnon Robert E.

(Last)

(First)

(Middle)

C/O BONE BIOLOGICS CORP

2 BURLINGTON WOODS DR. SUITE 100

(Street)

BURLINGTON

MASSACHUSETTS

01803

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Bone Biologics Corp [ BBLG ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/28/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Non-Employee Stock Option	$0.5	09/28/2026		A		113,896		⁽¹⁾	09/28/2036	Common Stock	113,896	$0	113,896	D
Non-Employee Stock Option	$5.28							⁽²⁾	06/04/2035	Common Stock	10,483		10,483	D
Non-Employee Stock Option	$10.38							⁽²⁾	09/17/2034	Common Stock	5,119		5,119	D
Non-Employee Stock Option	$25.44							⁽²⁾	01/08/2034	Common Stock	2		2	D
Non-Employee Stock Option	$25.44							⁽²⁾	01/08/2034	Common Stock	1,335		1,335	D

Explanation of Responses:

1. This option was granted under the Bone Biologics Corporation 2015 Equity Incentive Plan, in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, vests infour equal quarterly installments.

2. This option is fully exercisable as of the date of this report.

	/s/ Robert E. Gagnon	09/30/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR